中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2014年
7期
1428-1430
,共3页
许圆%周晓中%钱鸣杰%唐文
許圓%週曉中%錢鳴傑%唐文
허원%주효중%전명걸%당문
埃索美拉唑%骨密度%骨代谢%骨组织形态学%骨质疏松
埃索美拉唑%骨密度%骨代謝%骨組織形態學%骨質疏鬆
애색미랍서%골밀도%골대사%골조직형태학%골질소송
Esomeprazole%Bone mineral density%Bone metabolism%Bone histomorphometric analysis%Osteoporosis
目的 观察不同剂量的埃索美拉唑在不同时间点对雄性SD大鼠骨密度及骨代谢的影响.方法 将24只3个月龄雄性SD大鼠按体质量随机分为对照组(给予赋形剂)、小剂量组[按10 mg/(kg·d)的剂量给予埃索美拉唑]和大剂量组[按50 mg/(kg·d)的剂量给予埃索美拉唑].第0、8、14周时,检测每只大鼠全身骨密度及血清中骨碱性磷酸酶、抗酒石酸酸性磷酸酶和钙的浓度.处死大鼠后用组织形态学方法评估大鼠股骨结构改变.结果 与对照组比较,大剂量组中大鼠体质量增长明显受抑制(P＜0.05),第14周时骨密度明显降低,血清中骨碱性磷酸酶、抗酒石酸酸性磷酸酶和钙的浓度明显升高,分别为(198.51±6.98)、(1.49±0.04) U/L、(2.44±0.05) mmol/L,而第8周时3组间差异无统计学意义(P＞0.05).组织形态学显示14周时3组间的股骨结构差异明显,大剂量组空骨陷窝率明显高于对照组和小剂量组(P＞0.05).结论 大剂量应用埃索美拉唑导致雄性大鼠骨密度降低并影响其骨代谢,这种效应还存在一定的时间依赖性.
目的 觀察不同劑量的埃索美拉唑在不同時間點對雄性SD大鼠骨密度及骨代謝的影響.方法 將24隻3箇月齡雄性SD大鼠按體質量隨機分為對照組(給予賦形劑)、小劑量組[按10 mg/(kg·d)的劑量給予埃索美拉唑]和大劑量組[按50 mg/(kg·d)的劑量給予埃索美拉唑].第0、8、14週時,檢測每隻大鼠全身骨密度及血清中骨堿性燐痠酶、抗酒石痠痠性燐痠酶和鈣的濃度.處死大鼠後用組織形態學方法評估大鼠股骨結構改變.結果 與對照組比較,大劑量組中大鼠體質量增長明顯受抑製(P＜0.05),第14週時骨密度明顯降低,血清中骨堿性燐痠酶、抗酒石痠痠性燐痠酶和鈣的濃度明顯升高,分彆為(198.51±6.98)、(1.49±0.04) U/L、(2.44±0.05) mmol/L,而第8週時3組間差異無統計學意義(P＞0.05).組織形態學顯示14週時3組間的股骨結構差異明顯,大劑量組空骨陷窩率明顯高于對照組和小劑量組(P＞0.05).結論 大劑量應用埃索美拉唑導緻雄性大鼠骨密度降低併影響其骨代謝,這種效應還存在一定的時間依賴性.
목적 관찰불동제량적애색미랍서재불동시간점대웅성SD대서골밀도급골대사적영향.방법 장24지3개월령웅성SD대서안체질량수궤분위대조조(급여부형제)、소제량조[안10 mg/(kg·d)적제량급여애색미랍서]화대제량조[안50 mg/(kg·d)적제량급여애색미랍서].제0、8、14주시,검측매지대서전신골밀도급혈청중골감성린산매、항주석산산성린산매화개적농도.처사대서후용조직형태학방법평고대서고골결구개변.결과 여대조조비교,대제량조중대서체질량증장명현수억제(P＜0.05),제14주시골밀도명현강저,혈청중골감성린산매、항주석산산성린산매화개적농도명현승고,분별위(198.51±6.98)、(1.49±0.04) U/L、(2.44±0.05) mmol/L,이제8주시3조간차이무통계학의의(P＞0.05).조직형태학현시14주시3조간적고골결구차이명현,대제량조공골함와솔명현고우대조조화소제량조(P＞0.05).결론 대제량응용애색미랍서도치웅성대서골밀도강저병영향기골대사,저충효응환존재일정적시간의뢰성.
Objective This study aimed to investigate the effects of different doses of esomeprazole use of male SD rats bone mineral density and bone metabolism at different time points in order to guide clinical treatment.Methods Twenty four 3-month-old male rats were divided into three groups:the control group received the vehicle only,the low-dose esomeprazole group was treated with esomeprazole of 10 mg/ (kg·d) and the high-dose esomeprazole group was treated with esomeprazole of 50 mg (kg· d).We assess total bone mineral densities (BMDs) and bone alkaline phosphatase (B-ALP),tartate resistant acid phosphatase 5b (TRACP 5b) and serum calcium concentration at weeks 0,8 and 14.Bone histomorphometric analysis was performed to evaluate the structural changes in the femur of rats after sacrifice.Results The body weight of the high-dose esomeprazole group was suppressed whereas that of the control group increased significantly at week 8 (P ＜ 0.05).The BMD of the high-dose group decreased dramatically whereas that of the other two groups increased significantly at week 14.Serum B-ALP,TRACP 5b and calcium concentrations increased significantly which is (198.51 ± 6.98),(1.49 ± 0.04) U/L and (2.44 ± 0.05) mmol/L respectively.Significant changes in the results were not observed at week 8 (P ＞ 0.05).Bone histomorphometric analysis showed significantly different bone structures among the three groups at week 14 and the ER of the high-dose group was significantly higher than the control group and thelow-dose group.Conclusion Long term and high dose use of esomeprazole reduces bone mineral density and effects bone metabolism of male rats in a time-dependent manner.
